Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.76 |
| ▸ | NPY2R | P49146 | 7/20 | 0.59 |
| ▸ | NPY4R | P50391 | 7/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.59 |
| ▸ | NPY1R | P25929 | 5/20 | 0.59 |
| ▸ | REN | P00797 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin SCHEMBL29350537 | 0.97 | AGTR2 (0.70) | AGTR2AGTR1NPY2RNPY4RNPY5R | |
| Angiotensin Ii SCHEMBL13232382 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL2566771 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL1189 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL14990505 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL21267957 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL3465991 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Talfirastide SCHEMBL29367137 | 0.94 | AGTR2 (0.73) | AGTR2AGTR1NPY2RNPY4RNPY5R | |
| Angiotensin Ii SCHEMBL1585377 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL8898391 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630822-B2 | Treatment of heart failure in human subjects | NOVO NORDISK A/S (DK) | 2026-05-19 | — | — | US | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3691668-B1 | TREATMENT FOR THERAPY REFRACTORY DEPRESSION WITH GLYCYRRHIZIN | MURCK HARALD (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4713435-A1 | METHODS OF CULTURING CARDIAC CELLS AND USE OF CELLS FOR DISEASE MODELING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2026-03-25 | — | — | EP | claimed |
| US-12564615-B2 | Treatment method for cardiac hypertrophy | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-03 | — | — | US | claimed |
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | claimed |
| EP-3518898-B1 | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY | CHILDRENS MEDICAL CT CORP (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4000608-B1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | claimed |
| EP-3529251-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2022-10-05 | — | — | EP | claimed |
| US-20220243204-A1 | TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS | NOVO NORDISK A/S (DK) | 2022-08-04 | — | — | US | claimed |
| CN-114828896-A | Virus-mimicking nanoparticles | 雷根斯堡大学 | 2022-07-29 | — | — | CN | claimed |
| EP-3043824-B1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | SCRIPPS RESEARCH INST (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3492466-B1 | ORAL SOLID PREPARATION AND USE THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2022-06-01 | — | — | EP | claimed |
| EP-3207940-B1 | COMPOSITIONS OF A NEUREGULIN FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE | ZENSUN SHANGHAI SCIENCE & TECH CO LTD (CN) | 2022-06-01 | — | — | EP | claimed |
| CN-114450067-A | Treatment of heart failure in human subjects | 卡迪奥尔药物有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | claimed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | claimed |
| WO-2022036506-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | 天津睿创康泰生物技术有限公司 | 2022-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564615-B2 | Treatment method for cardiac hypertrophy | TNNT2, ADIPOR1, AGTR1 | AGTR2 9/4885AGTR1 3/4885NPY2R 1055/4885 |
| US-12630822-B2 | Treatment of heart failure in human subjects | SLC5A2, SLC5A1, DPP4 | AGTR2 7/4885AGTR1 8/4885NPY2R 827/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR2 13/4885AGTR1 4/4885NPY2R 58/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | AGTR2 910/4885AGTR1 453/4885NPY2R 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.